← Eichor
Study identifier: NCT06219135 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of the Performance of the IDBIORIV Method in Pathogen Identification and Antibiotic Susceptibility Testing in Patients With Sepsis

Condition: Sepsis  ·  Sponsor: Hospices Civils de Lyon

PhaseN/A
Planned participants1372
Who can joinAll sexes, 1 Day to no upper limit
Healthy volunteersNo

About this study

Sepsis is a disruption of homeostasis in the human body in response to bloodstream infection and is associated with a high risk of mortality. Worldwide, sepsis is affecting approximately 30 million people and resulting in six million deaths. Blood culture is a specific blood sample used to identifying microbial agent (bacterium or yeast) and determine the sensitivity of these microorganisms to antibiotics and antifungals. Any delay in identifying the microorganism and/or determining the AST (antibiotic susceptibility testing) has a direct impact on the administration of appropriate antibiotic treatment and, consequently, on mortality of the patient. The faster the diagnosis, the faster the antibiotic treatment will be adapted, the higher the survival rate/probability of patients, and the lower the ecological impact. In routine, clinical microbiology laboratories currently use 2 automatized techniques: MALDI-TOF MS® for microorganisms identification and VITEK2® method for AST determination. Based on a proteomic approach, the IDBIORIV method is a rapid method (90 minutes) in comparison of current methods (24/48 hours) able to identifying a large panel of 113 pathogens and determine the antibiotic resistance profile of 49 species for 4 classes of antibiotics (Beta-lactams, Aminosides, Glycopeptides, Colistin). The main objective of this study is to evaluate the performance of the IDBIORIV method in pathogen identification and antibiotic susceptibility testing in comparison…

This description comes directly from the study's public registry record.

Talk to the study team

François VANDENESCH, Pr  ·  4 72 07 11 11  ·  francois.vandenesch@univ-lyon1.fr

Always discuss trial participation with your own doctor first.

Locations (23)

Femme Mère enfant HospitalBron, FranceRecruiting
Femme Mère Enfant HospitalBron, FranceRecruiting
Femme Mère enfant HospitalBron, FranceNot Yet Recruiting
Louis Pradel HospitalBron, FranceRecruiting
Louis Pradel HospitalBron, FranceRecruiting
Louis Pradel HospitalBron, FranceRecruiting
Pierre Wertheimer HospitalBron, FranceRecruiting
Edouard Herriot HospitalLyon, FranceRecruiting
Edouard Herriot HospitalLyon, FranceRecruiting
Edouard Herriot HospitalLyon, FranceNot Yet Recruiting
Edouard Herriot HospitalLyon, FranceNot Yet Recruiting
Croix Rousse HospitalLyon, FranceRecruiting

+ 11 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06219135